Cd20 B Cell Marker
Cd20 B Cell Marker - Related Videos
10:56
Co-localization of Cell Lineage Markers and the Tomato Signal
0 Views •
Cited by 18 •
2016
We developed two sets of tracing combinations in Rosa26tdtomato (ubiquitously expressed in all cells)/Cre (specifically expressed in chondrocytes) mice: one with 2.3Col1a1-GFP (specific to osteoblasts) and one with immunofluorescence (specific to bone cells). The data demonstrate the direct transformation of chondrocytes into bone cells.
10:32
Cell Surface Marker Mediated Purification of iPS Cell Intermediates from a Reprogrammable Mouse Model
0 Views •
Cited by 21 •
2014
Mouse embryonic fibroblast can be reprogrammed into induced pluripotent stem cells at low efficiency by the forced expression of transcription factors Oct-4, Sox-2, Klf-4, c-Myc. The rare intermediates of the reprogramming reaction are FACS isolated via labeling with antibodies against cell surface makers Thy-1.2, Ssea-1, and Epcam.
03:20
Labeling Neural Cell Surface Markers with Azidosugar while Co-culturing with Endothelial Cells
0 Views •
2025
This video demonstrates a protocol for co-culturing mouse brain endothelial cells and primary cortical stem cells and labeling the cell surface glycoproteins using Ac4ManNAz (azidosugar per-O-acetylated N-azidoacetylmannosamine). This method allows for selective enrichment and identification of cell surface proteins in primary cells.
05:35
CD Marker Recognition of Human Cytokine-Induced Killer Cells by Flow Cytometry
0 Views •
2025
In this video, we demonstrate a flow cytometry-based technique to determine the proportion of cytokine-induced killer T-cells, CIK cells, expanded from a peripheral blood mononuclear cell culture.
11:39
Identifying Cell Surface Markers of Primary Neural Stem and Progenitor Cells by Metabolic Labeling of Sialoglycan
0 Views •
Cited by 1 •
2019
Presented here is a protocol that combines an in vitro neural-endothelial co-culture system and metabolic incorporation of sialoglycan with bioorthogonal functional groups to expand primary neural stem and progenitor cells and label their surface sialoglycoproteins for imaging or mass-spectrometry analysis of cell surface markers.
FAQs
CD20 appears on most developing and mature B cells but is generally absent from plasma cells. Consequently, CD20 detection supports recognition of many B-cell populations, whereas a CD20-negative result does not by itself exclude a cell from the broader B-cell lineage. This distinction is important when comparing cellular composition across tissues or disease states.
As a transmembrane protein, CD20 associates with membrane signaling complexes and helps regulate calcium flux during B-cell receptor activation. This links the marker to a functional signaling context rather than making it merely a label for cell identification. Studies can therefore examine CD20-positive populations while considering how receptor-associated signaling may shape B-cell responses.
CD20 abundance reflects the presence and distribution of cells that express the marker, but staining alone does not measure every aspect of B-cell activity. Interpretation should account for developmental identity, the relative absence of CD20 from plasma cells, and the tissue or disease context. This prevents marker detection from being treated as a complete measure of immune function.
Flow cytometry, immunohistochemistry, and immunofluorescence provide complementary ways to detect CD20. Flow cytometry supports classification of immune-cell populations, while tissue-based immunohistochemistry or immunofluorescence can show marker distribution within lymphoid tissues. The choice depends on whether the study prioritizes population classification or spatial localization of B cells.
Researchers can compare CD20-positive cell distributions in health, infection, and disease, including changes within lymphoid tissues. Such measurements help characterize how B-cell populations are represented during an immune response. Because CD20 identifies a defined marker-positive compartment rather than all immune activity, findings are most informative when interpreted as changes in B-cell distribution or representation.
Therapeutic antibodies can target CD20, allowing experiments to examine B-cell depletion and immune regulation. Measuring CD20-positive populations before or after such treatment can help assess changes in the targeted compartment. In infection research, this creates a way to relate altered B-cell representation to immune responses in lymphoid tissues, while recognizing that plasma cells are generally not CD20-positive.